A recent study indicates that people who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Research printed in a prominent health publication points out that while obese individuals often shed substantial amounts of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing such medications need to be cognizant of the danger of fast rebound weight gain when the treatment ends," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight within about 18 months.
Comparing Therapies
The analysis, which looked at 37 of studies involving thousands of patients, compared the effects of the injectable medications with other pills.
Researchers emphasize that people who shed pounds through dieting typically have a more gradual creep back—approximately 100 grams monthly—post-intervention.
Understanding the Quick Regain
Experts suggest the mode of action of the drugs explains the heightened rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to hunger is uncontrolled, making overeating a significant risk."
A Chronic Condition?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, given the likelihood of weight regain, the therapy might need to be life-long.
This view is echoed by drug manufacturers, who say that the results "emphasize the chronic nature of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have come off the medication report a powerful resurgence of appetite.
"I experienced something activating and I was suddenly starving," said an individual.
This difficulty is exacerbated if individuals have not established sustainable lifestyle or habit modifications during therapy.
Widespread Use
Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Use is more common among females than males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and long-term success hinges on combined behavioural support.
